Eikon Therapeutics, Inc.
corporate_fare Company Profile
Eikon Therapeutics, Inc. (NASDAQ:EIKN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for EIKN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for EIKN spans 8-K, 10-Q, 10-K, SCHEDULE 13D.
Recent high-impact activity:
- Eikon Posts $86.1M Q3 Loss, Cash Runway Extended Into Q1 2028
- Eikon's EIK1001 Hits 63.1% ORR in First-Line NSCLC at ESMO 2026
- Eikon Presents ESMO Data Across Three Programs, Including First Clinical Results for EIK1004 and EIK1005
- Eikon Therapeutics Updates Corporate Presentation with New Clinical Data and Milestones
- Eikon Therapeutics Q2 2026: Losses Continue, Material Weakness Unresolved
Short Interest & Short Volume
10.47 days to coverFINRA reported short interest of 5,536,871 shares in EIKN as of the October 30, 2026 settlement, a 13.1% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 61.3% of EIKN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.